Altered pharmacokinetics of piperacillin in febrile neutropenic patients ...

2 downloads 0 Views 493KB Size Report
Mar 31, 2014 - Robertson,a,b Sue Yeend,e Andy Phay,e Sheila Lehman,d Jeffrey Lipman,f,g Sandra L Peake,h. 4. Jason A Robertsa,f,g. 5. School of ...
AAC Accepts, published online ahead of print on 31 March 2014 Antimicrob. Agents Chemother. doi:10.1128/AAC.02340-14 Copyright © 2014, American Society for Microbiology. All Rights Reserved.

1

Altered pharmacokinetics of piperacillin in febrile neutropenic patients with haematological

2

malignancy

3

Fekade Bruck Sime,a,b,# Michael S Roberts,a,b Morgyn S Warner,c Uwe Hahn, d Thomas A

4

Robertson,a,b Sue Yeend,e Andy Phay, e Sheila Lehman, d Jeffrey Lipman,f,g Sandra L Peake,h

5

Jason A Robertsa,f,g

6

School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australiaa;

7

Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The

8

Queen Elizabeth Hospital, Adelaide, Australiab; SA Pathology and the University of Adelaide,

9

Adelaide, Australiac; Department of Haematology/Oncology, The Queen Elizabeth Hospital,

10

Adelaide, Australiad; Cancer Clinical Trials, The Queen Elizabeth Hospital, Adelaide, Australiae;

11

Royal Brisbane and Women’s Hospital, Herston, Brisbane, Queensland, Australiaf; Burns,

12

Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane,

13

Queensland, Australiag; Department of Intensive Care Medicine, The Queen Elizabeth Hospital,

14

Adelaide, Australiaf.

15

Running Head: Kinetics of piperacillin in febrile neutropenia

16

#Address correspondence to Fekade B. Sime, [email protected]

1

17

Abstract

18

This study assessed the pharmacokinetics and dosing adequacy of piperacillin in febrile

19

neutropenic patients after the first dose. Pharmacokinetic analysis was performed using non-

20

compartmental methods. We observed elevated volume of distribution (29.7 ± 8.0 L) and

21

clearance (20.2 ± 7.5 L/h) compared to data from other patient populations. Antibiotic exposure

22

did not consistently achieve therapeutic targets. We conclude that alternative dosing strategies

23

guided by therapeutic drug monitoring may be required to optimise exposure.

24

Key words: piperacillin, pharmacokinetics, febrile neutropenia, haematological malignancy,

25

pharmacodynamics

2

26

Febrile neutropenia is a medical emergency associated with high mortality (1). Immediate

27

administration of broad-spectrum antibiotics is crucial to reduce the risk of mortality (2). Beta-

28

lactam antibiotics active against Pseudomonas aeruginosa, such as piperacillin–tazobactam, are

29

common first line empiric agents for this condition. Emerging data suggest that standard dosing

30

regimens of these antibiotics may not provide adequate exposure due to pharmacokinetic (PK)

31

alterations emanating from pathophysiological processes associated with neutropenia (3, 4).

32

More specifically, the proportion of the dosing interval that the free drug concentration remains

33

above the minimum inhibitory concentration (fT>MIC) may be diminished. For beta-lactams,

34

fT>MIC is the pharmacokinetic/pharmacodynamic (PK/PD) index that best correlates with clinical

35

outcome (5).

36

Most of the evidence for altered beta-lactam PK and associated poor PK/PD target attainment in

37

febrile neutropenic patients is available for other antibiotics such as ceftazidime (6) and

38

meropenem (7). Data is meagre for piperacillin in this regard even though it is commonly

39

considered the preferred beta-lactam for febrile neutropenia. To our knowledge, there is no well

40

described recent study except the works of Drusano et al (8, 9) which reported no PK alterations

41

in febrile neutropenic patients, a finding which is contrary to the recent reports of PK alterations

42

and variability across many antibiotic classes (3, 4). The aim of this study was, therefore, to

43

describe the PK of piperacillin in patients with febrile neutropenia following chemotherapy for

44

hematological malignancy as well as assess the adequacy of the standard initial dosing to attain

45

recommended pharmacodynamic (PD) target against all possible organisms during the first

46

dosing interval.

47

Twelve patients with haematological malignancies, aged ≥ 18 years, were enrolled when

48

prescribed to receive piperacillin-tazobactam after developing febrile neutropenia.

49

neutropenia was defined as the presence of a single oral temperature of ≥ 38.3°C (101°F) or a

Febrile

3

50

temperature of ≥ 38.0°C (100.4°F) for >1 h, with a neutrophil count < 500 cells/mm3; or a count

51

< 1,000 cells/ mm3, with a predicted decrease to 500 U/L) or if pregnant. Ethics approval was granted from

54

the local Human Research Ethics Committee. All patients received 4.5 g piperacillin-tazobactam

55

every eight hours via intravenous bolus infusion over 30 minutes followed by 15 to 20 minutes

56

line flushing. In addition all patients received a single gentamicin 7 mg/kg dose.

57

Serial blood samples were collected just prior to the first dose, then at the end of line flushing,

58

and then at 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, and 7hrs after the start of infusion and a final sample just

59

before the second dose. Total plasma concentrations of piperacillin were quantified using a

60

validated liquid chromatography tandem mass spectrometry method. Non-compartmental

61

pharmacokinetic analysis was performed using PKSolver (10). fT>MIC was estimated after first

62

dose from the log-linear elimination phase. First the terminal elimination constant (Kel) was

63

estimated with PKSolver software (10). Then, considering 30% protein binding for piperacillin

64

(11), fT>MIC was calculated for P. aeruginosa and Enterobacteriaceae based on the break points

65

of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (12) and the

66

Clinical and Laboratory Standards Institute (CLSI)(13). As this study aims to assess adequacy of

67

initial dosing against all possible organisms, we selected P. aeruginosa and Enterobacteriaceae

68

which have the highest MIC breakpoints according to EUCAST and CLSI interpretive criteria.

69

Demographic characteristics of study participants are given in Table 1. All patients were febrile

70

and neutropenic with cell counts too low to perform differential counts. Blood cultures were

71

positive in four patients (patient 1, 3, 9 and 10) and organisms isolated were, an organisms

72

resembling Staphylococci, Enterobacter aerogenes, P. aeruginosa, and Escherichia coli

73

respectively. The plasma concentration-time profile for total piperacillin concentration after a 4

74

single dose of 4.5 g piperacillin-tazobactam is depicted in figure 1. Pharmacokinetic parameter

75

estimates of individual study participants are given in Table 2.

76

We observed elevated volume of distribution (Vd) (29.7 ± 8.0 L) and clearance (CL) (20.2 ± 7.5

77

L/h) for the cohort in this study. Different factors may contribute to the expansion of Vd. One

78

important factor is alteration of capillary permeability and subsequent extravasation of vascular

79

fluid during infection mediated by various factors (14). It could also occur due hypoalbuminemia

80

which is common in hematological malignancies and observed for all participants in this study

81

(Table 1). Low albumin concentrations reduce plasma oncotic pressure subsequently leading to

82

enhanced fluid extravasation. However, the effect of hypoalbuminemia is most prominent for

83

highly protein-bound antibiotics and therefore might have limited contribution towards the

84

increased piperacillin Vd observed in this study (30% protein binding) (4, 15). Changes in

85

glomerular filtration rate (GFR) have been implicated in the variability of antibiotic CL in febrile

86

patients with haematological malignancies (6). A very high value of GFR is common in patients

87

undergoing chemotherapy (16) and may contribute to elevated CL. Serum creatinine clearance

88

(Cockcroft-Gault) was also distinctively high for some participants (Table 1; patient 8 to 12)

89

indicating the presence of augmented renal clearance contributing to the significant increase in

90

individual piperacillin clearances (Table 2). In fact, drug exposure was moderately correlated

91

with creatinine clearance (r = - 0.663, P < 0.05). Augmented renal clearance in febrile patients

92

could occur perhaps in a similar way as in critically ill septic patients due to increased renal

93

blood flow secondary to a hyperdynamic cardiovascular state (17). However in hyperdynamic

94

patients where there is no stable creatinine concentration, predictive equations of creatinine

95

clearance as well as GFR are likely to be incorrect for assessment of the rapidly changing renal

96

function and hence antibiotic CL (18, 19).

5

97

The elevated CL and significant expansion of Vd in our patients explain the very low observed

98

trough concentrations (median; 0.5 mg/L). This is far below the clinical susceptibility breakpoint

99

of expected pathogens such as Enterobacteriaceae (8mg/L, EUCAST; 16 mg/L, CLSI) and P.

100

aeruginosa (16mg/L, CLSI and EUCAST) (12, 13). The fT>MIC achieved for P. aeruginosa after

101

the first dose (Figure 2) was sub-optimal as compared to the conventionally recommended PD

102

targets of about 50%-60% fT>MIC (20). Similarly, for Enterobacteriaceae fT>MIC was sub-optimal

103

for the majority of participants while referring to conventional PD targets, and in all patients

104

when considering 100% fT>MIC as a target. There is an emerging understanding that neutropenic

105

patients may require higher PK/PD index for successful outcome due to their compromised

106

immune response. Ariano et al. (21), for instance, showed that for meropenem, 80% clinical

107

response is observed when fT>MIC exceeds 75%, a value much higher than the conventional 40%

108

fT>MIC. Similarly, for penicillins and cephalosporins which lack post antibiotic effect against

109

Gram negative organisms, previous data from some animal studies have indicated that, in the

110

settings of profound neutropenia, free concentrations should be greater than the MIC for 90%–

111

100% of the dosing interval to ensure efficacy (22). This is well supported by studies that

112

demonstrate the profound effect of host immunity on PD parameters (23-25). In

113

immunocompromised hosts, a more aggressive antibiotic action through increased antibiotic

114

exposure time may be required to achieve the same response as in immunocompetent ones.

115

Considering 100% fT>MIC, our results indicate that the standard bolus dose of 4.5g piperacillin-

116

tazobactam every eight hours is unlikely to provide optimal exposure against P. aeruginosa and

117

Enterobacteriaceae (figure 2). Optimal exposure should be achieved as early as possible to

118

reduce the risk of mortality (26). In the current study, concentrations remained below the MIC of

119

P. aeruginosa for about 5 to 6 hours of the first dose interval. Such extended sub-inhibitory

120

exposure should be avoided to reduce the risk of selection of resistant organisms (27). 6

121

We believe that the present intermittent dosing regimen should be reviewed and replaced with

122

new dosing strategies that ensure adequate antibiotic exposure and reduce the risk of emergence

123

of antibiotic resistance. Better exposure can be achieved with more frequent administration of the

124

dose (e.g. 4.5 g every six hourly) which in effect increases the total daily dose. The mode of

125

administration used (i.e 30 minutes bolus infusion) could also be optimized. The use of extended

126

(EI) or continuous infusion (CI) is one attractive approach to maximize fT>MIC without

127

increasing the total daily dose (28). In combination with a loading dose, EI or CI can be used to

128

avoid the initial sub-optimal exposure observed with the intermittent schedule in this study. CI

129

may be practically challenging as it requires a dedicated IV line which may not be available

130

given patients are often receiving a number of other drugs and perhaps nutrition support. EI is

131

more practical in this regard allowing sufficient line access for other purposes. Another challenge

132

is that, a fixed EI or CI regimen may not achieve PD target consistently in all patients due to the

133

variability in CL as well as Vd. Dose individualization through TDM may be useful to ensure

134

optimal exposure in every patient.

135

Often culture results are not available initially for use in TDM. We therefore suggest initial

136

dosing aiming at organisms with high MIC such as P. aeruginosa and then dosing can be

137

readjusted based on the specific organism MIC. Local institutional antibiograms should be

138

utilized whenever available as there is geographical and institution-to-institution variability in

139

susceptibility. However, in the absence of such data, EUCAST/CLSI breakpoints would provide

140

reasonable reference to use for TDM. This has been well demonstrated for piperacillin (and other

141

beta-lactam antibiotics) in critically ill patients who exhibit similar PK alterations as observed in

142

this study (29). However, it has not yet been described in febrile neutropenic patients. Further

143

clinical studies are required to assess the utility of TDM of piperacillin in febrile neutropenic

144

patients. 7

145

In conclusion, the observed high Vd as well as CL suggest altered PK of piperacillin in febrile

146

neutropenic patients. Standard intermittent dosing of 4.5g piperacillin-tazobactam (IV bolus,

147

every eight hours) resulted in sub-optimal antibiotic exposure and therefore was not sufficient.

148

We recommend TDM guided optimization with EI or adjusted dosing frequency to ensure

149

exposure to inhibitory concentrations for the entire dosing interval.

8

150

List of Acronyms

151

CI

Continuous infusion

152

CL

Clearance

153

CLSI

Clinical and Laboratory Standards Institute

154

EI

Extended infusion

155

EUCAST

The European Committee on Antimicrobial Susceptibility Testing

156

fT>MIC

Proportion of the dosing interval free drug concentration remains above MIC

157

GFR

Glomerular filtration rate

158

MIC

Minimum Inhibitory Concentration

159

PD

Pharmacodynamic

160

PK

Pharmacokinetic(s)

161

Vd

Volume of distribution

162

Vss

Volume of distribution at steady state

163

Competing interests

164

None

165

Acknowledgments

166

None

9

167

REFERENCE

168

1.

Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. 2005. Incidence, cost, and

169

mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-

170

1924.

171

2.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R,

172

Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002. 2002 guidelines for the use of

173

antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-751.

174

3.

Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C. 2008.

175

Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of

176

febrile neutropenia. Lancet Infect. Dis. 8:612-620.

177

4.

antimicrobial therapy in patients with cancer. Clin. Infect. Dis. 54:1785-1792.

178 179

Theuretzbacher U. 2012. Pharmacokinetic and pharmacodynamic issues for

5.

Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in

180

determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol.

181

Infect. Dis. 22:89-96.

182

6.

Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. 2005.

183

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of

184

continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob.

185

Agents Chemother. 49:3550-3553.

186

7.

Nyhlen A, Ljungberg B, Nilsson-Ehle I. 1997. Pharmacokinetics of meropenem in

187

febrile neutropenic patients. Swedish study group. Eur. J. Clin. Microbiol. Infect. Dis.

188

16:797-802.

10

189

8.

Drusano GL, de Jongh C, Newman K, Joshi J, Wharton R, Moody MR, Schimpff

190

SC. 1985. Moxalactam and piperacillin: a study of in vitro characteristics and

191

pharmacokinetics in cancer patients. Infection 13:20-26.

192

9.

Drusano GL, Forrest A, Plaisance KI, Wade JC. 1989. A prospective evaluation of

193

optimal sampling theory in the determination of the steady-state pharmacokinetics of

194

piperacillin in febrile neutropenic cancer patients. Clin. Pharmacol. Ther. 45:635-641.

195

10.

Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: An add-in program for

196

pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput.

197

Methods Programs Biomed. 99:306-314.

198

11.

Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA.

199

2013. Protein Binding of beta-Lactam Antibiotics in Critically Ill Patients: Can We

200

Successfully Predict Unbound Concentrations? Antimicrob. Agents Chemother. 57:6165-

201

6170.

202

12.

EUCAST, 20 Novermber 2013, access date. Breakpoint tables for interpretation of MICs

203

and zone diameters. [Online.]

204

[http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_

205

table_v_3.1.pdf]

206

13.

CLSI. 2013. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-

207

Third Informational Supplement. CLSI document M100-S23 Wayne, PA: Clinical and

208

Laboratory Standards Institute;.

209

14.

Maeda H. 2012. Vascular permeability in cancer and infection as related to

210

macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug

211

targeting. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 88:53-71.

11

212

15.

Ursula Theuretzbacher, Zeitlinger M. Antibacterial Distribution and Drug–Drug

213

Interactions in Cancer Patients, p. 443-454. In Safdar A (ed.), Principles and Practice of

214

Cancer Infectious Diseases. Springer Science+Business Media, New York.

215

16.

Roy AC, Jones DN, Slavotinek JP, Kichenadasse G, Karapetis C, Lam E, Bishnoi S,

216

Koczwara B. 2011. Very high GFR in cancer patients undergoing chemotherapy:

217

prevalence, carboplatin dosing patterns and chemotherapy toxicity. Asia Pac. J. Clin.

218

Oncol. 7:281-286.

219

17.

Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. 2010. Augmented

220

renal clearance in the Intensive Care Unit: an illustrative case series. Int. J. Antimicrob.

221

Agents 35:606-608.

222

18.

Chacko J. 2013. Assessment of renal function in the critically ill - Shall we look beyond predictive equations? Indian J. Crit. Care Med. 17:65-66.

223 224

19.

Star RA. 1998. Treatment of acute renal failure. Kidney Int. 54:1817-1831.

225

20.

Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.

226 227

21.

Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. 2005.

228

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients

229

with bacteremia. Ann. Pharmacother. 39:32-38.

230

22.

Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.

231

23.

Gerber AU, Brugger HP, Feller C, Stritzko T, Stalder B. 1986. Antibiotic therapy of

232

infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice:

233

comparison of murine and human pharmacokinetics. J. Infect. Dis. 153:90-97.

234 235

24.

Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF. 1986. Continuous versus intermittent administration of ceftazidime in experimental

12

236

Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob. Agents

237

Chemother. 30:403-408.

238

25.

Casal J, Gimenez MJ, Aguilar L, Yuste J, Jado I, Tarrago D, Fenoll A. 2002. Beta-

239

lactam activity against resistant pneumococcal strains is enhanced by the immune system.

240

J. Antimicrob. Chemother. 50 Suppl S2:83-86.

241

26.

Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS,

242

Goyal M. 2010. Impact of time to antibiotics on survival in patients with severe sepsis or

243

septic shock in whom early goal-directed therapy was initiated in the emergency

244

department. Crit. care Med. 38:1045-1053.

245

27.

Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. 2002.

246

Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among

247

hospitalized patients. Antimicrob. Agents Chemother. 46:854-858.

248

28.

has the time come? Curr. Opin. Infect. Dis. 25:619-625.

249 250

Abbott IJ, Roberts JA. 2012. Infusional beta-lactam antibiotics in febrile neutropenia:

29.

Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL,

251

Lipman J. 2010. Therapeutic drug monitoring of beta-lactams in critically ill patients:

252

proof of concept. Int J Antimicrob Ag 36:332-339.

13

Table 1. Characteristics of the study participants

Patient

1 2 3 4 5 6 7 8 9 10 11 12

Heamatological Malignancy

Acute Myeloid Leukaemia Acute Myeloid Leukaemia Acute Myeloid Leukaemia Multiple Myeloma Lymphoma Acute Myeloid Leukaemia Acute lymphoblastic leukaemia Acute lymphoblastic leukaemia Acute Myeloid Leukaemia Multiple Myeloma Multiple Myeloma Multiple Myeloma

Median (Interquartile Range) a

Sex

Age (yr)

Body Weight (Kg)

Height (cm)

Serum Creatinine (µmol/L)

Creatinine Clearancea (ml/min/1.73 m2)

Albumin (g/L)

172 175 164 153 155 173

88 61 57 67 78 95

65.3 73.7 72.6 62.8 55.4 51.4

Liver enzymes (U/L) ALT

AST

27 25 29 28 26 33

50 13 37 16 27 21

23 7 23 24 19 48

M

61

M

74

F

70

F

64

F

74

M

79

82 100 64 53 54 69

M

68

63

175

70

78.6

23

25

15

171 184 174 184 182

44 66 46 61 68

119.6 96.9 109.7 110.4 85.2

27 26 31 30 31

14 142 12 37 53

10 102 14 19 28

173.5 (169.2-176.7)

66.5 (60.0-72.0)

76.1 (64.7-100.1)

27.5 (26.0-30.2)

26 (15.5 -40.2)

21.0 (14.7-25.0)

F

54

M

63

M

65

M

53

M

59

71 79 100 91 103

64.5 (60.5-71.0)

75.0 (63.7-93.2)

Cockcroft -Gault

253 254 255 256 257 14

Table 2. Pharmacokinetic parameter estimates of piperacillin after a single dose of 4.5g piperacillin-tazobactam in twelve febrile neutropenic patients with haematological malignancies Patients

Cmax (mg/L)

Cmin (mg/L)

AUC 0-t (mg/L*h)

AUC 0-inf (mg/L*h)

AUMC 0-inf (mg/L*h^2)

MRT (h)

Vz (L)

Vss (L)

CL (L/h)

t1/2 (h)

1

125.7

0.5

174.6

175.5

285.3

1.4

38.3

31.4

22.8

1.2

2

119.5

1.1

196.4

198.1

343.9

1.5

31.6

30.0

20.2

1.1

3

144

0.5

239.0

239.7

409.8

1.5

23.8

24.4

16.7

1.0

4

228

6.1

419.4

433.1

1026.4

2.1

20.7

19.6

9.2

1.6

5

148.5

2.5

292.6

297.2

618.9

1.8

25.0

24.7

13.5

1.3

6

129.5

5.2

283.8

298.1

772.9

2.3

36.6

31.4

13.4

1.9

7

180.5

0.9

288.9

290.2

493.1

1.4

19.8

20.0

13.8

1.0

8

161.5

0.2

238.6

238.8

346.3

1.2

17.9

20.1

16.7

0.7

9

97.5

0.2

150.1

150.4

234.5

1.3

40.7

34.8

26.6

1.1

10

92.65

0.4

143.2

143.8

247.7

1.5

48.6

41.0

27.8

1.2

11

86.6

0.2

124.0

124.3

180.0

1.2

37.9

38.6

32.2

0.8

12

89.8

-

130.1

133.4

215.5

1.4

38.1

41.0

30.0

0.9

Mean ± SD Median (Interquartile Range)

133.6 ± 42.2 127.6 (96.3-151.8)

1.6 ± 2.1 0.5 (0.3-1.8)

223.4 ± 88 217.5 (148.4 -285.1)

226.9 ±91.6 218.4 (148.8 -291.9)

431.2 ± 257.4 345.1 (244.4 -524.6)

1.6 ± 0.4 1.5 (1.4-1.6)

31.6 ± 9.9 34.1 (23-38.2)

29.7 ± 8.0 30.7 (23.3-35.7)

20.2 ± 7.5 18.5 (13.7-26.9)

1.1 ± 0.3 1.1 (1.0-1.2)

258 259 260 15

261

List of Figures

262

Figure 1. Plasma concentration-time profile for total piperacillin concentration after single

263

dose of 4.5g piperacillin-tazobactam in twelve febrile neutropenic patients with

264

haematological malignancies.

265

Figure 2. Pharmacodynamic target attainment after a single dose of 4.5g piperacillin-

266

tazobactam in twelve febrile neutropenic patients with haematological malignancies

267

(considering EUCAST MIC breakpoints for Entereobacteriaceae and P. aeruginosa.)

16

Total Plasma concentrattion (mg/L) e range) Median (Interquartile

1000

100

10

1

0.1 0

1

2

3

4

5

6

7

8

9

Time (hr)

Figure 1. 1 Plasma concentration-time concentration time profile for total piperacillin concentration after single dose of 44.5g 5g piperacillin-tazobactam in twelve febrile neutropenic patients with haematological malignancies.

100% 90%

P. aeruginosa (16 mg/L)

80%

Enterobacteriaceae (8 mg/L)

ffT>MIC

70% 60% 50% 40% 30% 20% 10% 0% P1

P2

P3

P4

P5

P6

P7

P8

P9

P10 P11 P12

Patients

Figure 2. Pharmacodynamic target attainment after a single dose of 4.5g piperacillin-tazobactam in twelve febrile neutropenic patients with haematological malignancies (considering EUCAST MIC breakpoints for Entereobacteriaceae and P. aeruginosa.).